Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Biden’s Center for Medicare and Medicaid Services extends coverage by making nonsense of the law.

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly’s ...

Dear S.R.: Tirzepatide (Zepbound), like semaglutide, is a prescription medication originally used for diabetes but now ...

This is a prescription medication originally used for diabetes but now approved for weight loss. Most people regained weight ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...

With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and ...

WEDNESDAY, Nov. 27, 2024 (HealthDay News) -- The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

My husband and I have started taking Zepbound for various medical reasons. The medication has significantly and positively ...